DLBS3233 Reduces Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) and Increases Peroxisome Proliferator-Activated Receptor Gamma and Nephrin in Diabetic Rat Podocytes
- Glomerular Diseases: Podocyte Biology - II
November 04, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1403 Podocyte Biology
- Mohani, Chandra Irwanady, Universitas Brawijaya, Malang, Jawa Timur, Indonesia
DLBS3233 is a standardized extract derived from Cinnamomum burmanii and Lagerstroaemia speciosa, has shown antidiabetic effects. Here, we sought to explore the potential benefits of DLBS3233 to regulate insulin signaling in renal podocytes cell, represented by HOMA-IR, as well as podocytes PPAR gamma and Nephrin in diabetic rats with insulin resistance.
Thirty adult male Wistar rats were randomly divided into six groups (n=5 per group): nondiabetic rat group as a negative control (group I); untreated diabetic rats (group II), diabetic rats treated with DLBS3233 4,5mg/kgBB (group III); 9mg/kgBB (group IV); 18mg/kgBB (group V), and diabetic rats treated with pioglitazone (group VI). We checked HOMA-IR to confirm the occurrence of insulin resistance before and after administration of DLBS3233 in a group of rats with diabetes. Convocal examination was performed to examine the expression of PPARγ and Nephrin. The data were analyzed using paired t-test and ANOVA for pre and post DLBS3233 for HOMA IR.
Administration of DLBS3233 showed work on improving insulin resistance from a significant decrease in HOMA-IR compared to the control group (p <0.05). Increased expression of PPARg and Nephrin also confirmed the effect of a significant improvement in insulin resistance (p<0.05).
DLBS3233 was able to improve insulin sensitivity in diabetic rats with insulin resistance. The insulin sensitizing effect was projected from the reduction of HOMA-IR, increase of PPAR gamma and nephrin expression in renal podocytes cell. So further studies are needed to clinically test the efficacy of DLBS3233.